Bring precision medicine to the treatment of complex diseases such as autoimmunity and cancer.
Develop life-saving medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.
Individual cells are the building blocks of the human body. Their interactions and states define how we function in health and what goes wrong in disease. Single cell genomics allows us to interrogate individual cells in their natural context to see otherwise hidden biology.
We leverage the power of single-cell RNA sequencings to discover precision medicines for complex diseases such as autoimmunity and cancer. Understanding the cellular ecosystem of the disease and the complex interactions of these varied cell types is critical in creating effective treatments. Using sophisticated machine learning algorithms to analyze data of unprecedented size allows us to identify the specific cells that are causing the disease and which specific genes are triggering the malfunction within those cells. With this new level of clarity, our unique approach has the transformational potential to deliver the new wave of precision medicines.
Product engine
Constantly exploring new ideas and perspectives that motivate us to never stop innovating and making meaningful discoveries
Bringing our community together to create strong, collaborative relationships in an ecosystem that inspires us to work tirelessly to make a difference
Fiercely committed to responsibly executing with speed and excellence to bring transformative therapies to patients in need
March 24
First Clinical Candidate, Anti-TREM1 Antibody for IBD, Identified Through Novel SCOPE Platform; Phase 1 Study Anticipated in Early 2023 $83 Million in Additional Financing CAMBRIDGE, Mass. – March 24, 2022 – Celsius Therapeutics, a biotechnology company leveraging its human tissue-based platform to develop precision medicines for patients with cancer and autoimmune disease, today provided a […]
December 21
PARIS, France and CAMBRIDGE, Mass., US – December 21st, 2020 – Servier, a global pharmaceutical Group, and Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer and autoimmunity, today announced a strategic collaboration focused on the identification and validation of novel colorectal cancer (CRC) drug targets. “As colorectal cancer remains a leading contributor […]
You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.
